Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy

Lupus. 2006;15(12):881-5. doi: 10.1177/0961203306070970.

Abstract

We report one case of pregnancy-onset severe diffuse proliferative nephritis in a patient with systemic lupus erythematosus (SLE), who was successfully treated with a combination of anti-tumour necrosis factor (TNF)-alpha, plasmapheresis and high-dose intravenous gammaglobulin. No flares were observed either in clinical symptoms or in laboratory examinations during pregnancy or after delivery. Her autoantibodies except fluorescent anti-nuclear antibodies were negative. We suggest that a combination of anti-TNF-alpha, plasmapheresis and high-dose intravenous gammaglobulin may be a safe and effective therapy for pregnant patients suffering severe lupus nephritis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Combined Modality Therapy
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / administration & dosage*
  • Immunoglobulin G / adverse effects
  • Immunoglobulins, Intravenous*
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / adverse effects
  • Infant, Newborn
  • Lupus Nephritis / drug therapy*
  • Male
  • Plasmapheresis*
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Pregnancy Outcome
  • Receptors, Tumor Necrosis Factor / administration & dosage*

Substances

  • Immunoglobulin G
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Etanercept